10 Johnson & Johnson executives
Johnson & Johnson's Chairman and CEO Joaquin Duato and CFO Joseph Wolk open a group that also has the worldwide chairmen for pharmaceuticals and MedTech, the EVP for pharmaceutical R&D, the chief procurement officer, and Innovative Medicine's chief medical and North America operations officers. The retired CFO and DePuy Synthes's worldwide president round it out, useful for a partner learning how priorities are set across drugs and devices.
Professionals to explore
Dominic Caruso
LinkedInExperience: CFO · Johnson & Johnson
$6,731 per 30-minute call
Dominic Caruso describes being the "Retired CFO of Johnson & Johnson" and "the longest serving Chief Financial Officer (CFO) in Johnson & Johnson's 132-year history," with the CFO title dated from 2007. Caruso sits on the boards of Kyndryl and McKesson and the Cystic Fibrosis Foundation, so questions on long-run financial strategy at a healthcare company fit.
Is this you? Claim your profile and get paid for calls.
Jennifer Taubert
LinkedInExperience: Executive Vice President, Worldwide Chairman, Pharmaceuticals · Johnson & Johnson
$8,078 per 30-minute call
Since 2018, Jennifer Taubert has been Executive Vice President, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, and also describes the role as Worldwide Chairman, Innovative Medicine. Taubert was Company Group Chairman, The Americas Pharmaceuticals (2015-2018), Company Group Chairman, North America Pharmaceuticals (2012-2015) and President, Internal Medicine, North America Pharmaceuticals (2009-2011), so commercial pharmaceutical questions fit.
Is this you? Claim your profile and get paid for calls.
Joaquin Duato
LinkedInExperience: Chairman of the Board and Chief Executive Officer · Johnson & Johnson
$16,828 per 30-minute call
Chairman of the Board and Chief Executive Officer of Johnson & Johnson since 2023, Joaquin Duato was Chief Executive Officer from 2022 to 2023. Duato's other J&J titles include Vice Chairman of the Executive Committee (2018-2021), Executive Vice President, Worldwide Chairman, Pharmaceuticals (2011-2018) and Company Group Chairman, Diagnostics (2007-2009), so enterprise strategy questions fit best.
Is this you? Claim your profile and get paid for calls.
John C. Reed
LinkedInExperience: Executive Vice President, Pharmaceuticals, Research & Development · Johnson & Johnson Innovative Medicine
$8,078 per 30-minute call
Drug research is John C. Reed's area: Executive Vice President, Pharmaceuticals, Research & Development at Johnson & Johnson Innovative Medicine since 2023. Reed was EVP, Global Head of R&D at Sanofi (2018-2023) and Global Head of Roche Pharma Research & Early Development (pRED) at Roche (2013-2018), which makes this the person for pipeline and research partnership questions.
Is this you? Claim your profile and get paid for calls.
Joseph Wolk
LinkedInExperience: Executive Vice President, Chief Financial Officer · Johnson & Johnson
$6,731 per 30-minute call
As Executive Vice President, Chief Financial Officer of Johnson & Johnson since 2018, Joseph Wolk describes the job as stewarding the company's financial health. Wolk was Vice President, Investor Relations (2016-2018), CFO, Vice President, Finance - Global Pharmaceuticals (2014-2016) and Vice President, Finance - Medical Device Global Supply Chain (2010-2014), a fit for questions on how finance weighs pharma against devices.
Is this you? Claim your profile and get paid for calls.
Julian Hooks
LinkedInExperience: Former Senior Vice President, Chief Procurement Officer · Johnson & Johnson
$673 per 30-minute call
In 2025, Julian Hooks became Senior Vice President, Chief Procurement Officer at Johnson & Johnson, and was Senior Vice President, Global Services Procurement and Operations (2020-2024). Hooks also held Chief Procurement Officer titles for the Corporate Tier (2017-2020), Consumer Companies (2011-2017) and Janssen EMEA, Pharmaceutical Companies (2010-2011), so supplier selection questions fit best.
Is this you? Claim your profile and get paid for calls.
Mike D.
LinkedInExperience: Chief Medical Officer, Innovative Medicine · Johnson & Johnson
$3,365 per 30-minute call
A physician, Mike D. has been Chief Medical Officer, Innovative Medicine at Johnson & Johnson since 2026, and at Bayer was CMO, Executive VP MedAffairs&Pharmacovigilance and a member of the executive committee of Bayer's pharma division (2014-2026). Mike D. was also Senior VP, Global Medical Affairs & Pharmacovigilance at Bayer (2007-2014), a fit for drug safety and medical affairs questions.
Is this you? Claim your profile and get paid for calls.
Namal Nawana
LinkedInExperience: Worldwide President, DePuy Synthes · Johnson & Johnson
$4,039 per 30-minute call
Worldwide President, DePuy Synthes at Johnson & Johnson since 2025, Namal Nawana held the title Worldwide President Depuy Synthes Spine there from 2011 to 2012. Nawana was also Chairman and Founder of Sapphiros (2021-2025) and of Neoenta llc (2017-2025) and a Director at Hologic, Inc. (2018-2024), a fit for orthopaedics and medical device business questions.
Is this you? Claim your profile and get paid for calls.
Scott White
LinkedInExperience: Chief Operations Officer, NA Innovative Medicine · Johnson & Johnson Innovative Medicine
$2,019 per 30-minute call
The Strategic Customer Group is among the functions covered by Scott White's role as Chief Operations Officer, NA Innovative Medicine at Johnson & Johnson Innovative Medicine since 2023. White was Company Group Chairman North America Pharmaceuticals (2018-2023), and at The Janssen Pharmaceutical Companies of Johnson & Johnson held President, Immunology (2017-2018) and President, Oncology (2014-2017).
Is this you? Claim your profile and get paid for calls.
Tim Schmid
LinkedInExperience: Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson · Johnson & Johnson MedTech
$8,078 per 30-minute call
A MedTech organization described as "$27B" with "70,000+ employees" has had Tim Schmid as Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson since 2023. Schmid was Company Group Chairman, Asia Pacific, MedTech (2018-2023), Chief Strategic Customer Officer, Medical Devices (2016-2018) and President, Ethicon U.S. (2012-2015), a fit for questions on MedTech strategy and strategic customer relationships.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Enterprise priorities and capital allocation are questions for Joaquin Duato, Joseph Wolk or Dominic Caruso. For one side of the business, Jennifer Taubert, John C. Reed, Scott White and Mike D. cover pharmaceuticals and Innovative Medicine, while Tim Schmid and Namal Nawana cover MedTech and orthopaedics; Julian Hooks is the one to ask about becoming or staying a supplier.
Questions to take into the conversation
- 01How does a company with both a pharmaceutical and a medical device business decide where the next dollar of R&D goes?
- 02What does a supplier or partner need to show to win sponsorship from a worldwide chairman at a diversified healthcare company?
- 03How do drug safety and medical affairs teams shape launch and lifecycle decisions in a large innovative medicine business?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.